These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention

These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention
Ebos chief executive John Cullity says shareholders can expect more buying in Southeast Asia. (Image: Ebos)
Rebecca Stevenson
Listed healthcare and pet company Ebos says it sees investment potential in regenerative medicine firm Origin Biologics. Dual-listed Ebos reported its full-year result on Wednesday, with sales revenue exceeding A$13.2 billion (NZ$14.4b) for the first time. Ebos is known for its canny acquisitions and chief executive John Cullity said the company would continue its foray into Southeast Asia and medical devices, but there were also opportunities in the US. Ebos completed a major acquisition in 2022 when it purchased Lifehealthcare,...

More Markets

NZ sharemarket up 0.4% despite inflation report
Markets Market Close

NZ sharemarket up 0.4% despite inflation report

The S&P/NZX 50 Index closed at 13,344.96, up 55.75 points or 0.42%.

Graham Skellern 20 Oct 2025
What Infratil likes about Contact Energy
Infrastructure

What Infratil likes about Contact Energy

Infratil is keeping its options open, while TECT diversifies.

Disclosure breaches Class action against ANZ NZ continues
Finance

Disclosure breaches Class action against ANZ NZ continues

It comes as retrospective law tweaks fail to give relief.

Andy Macdonald 20 Oct 2025
Kiwi Capital Limited appoints Susan Peterson as chair
Finance

Kiwi Capital Limited appoints Susan Peterson as chair

New chair of Kiwibank parent company Kiwi Capital Ltd brings breadth of experience.

Staff reporters 20 Oct 2025